+

CA2367590A1 - Induction in vitro de cellules t specifiques a un antigene a l'aide d'immunogenes derives de cellules dendritiques-cellules tumorales ou de cellules dendritiques-cellules virales - Google Patents

Induction in vitro de cellules t specifiques a un antigene a l'aide d'immunogenes derives de cellules dendritiques-cellules tumorales ou de cellules dendritiques-cellules virales Download PDF

Info

Publication number
CA2367590A1
CA2367590A1 CA002367590A CA2367590A CA2367590A1 CA 2367590 A1 CA2367590 A1 CA 2367590A1 CA 002367590 A CA002367590 A CA 002367590A CA 2367590 A CA2367590 A CA 2367590A CA 2367590 A1 CA2367590 A1 CA 2367590A1
Authority
CA
Canada
Prior art keywords
cells
cell
tumor
dendritic
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002367590A
Other languages
English (en)
Inventor
Louis D. Falo, Jr.
Walter Storkus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2367590A1 publication Critical patent/CA2367590A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Cette invention concerne des cellules T spécifiques à un antigène, lesquelles sont obtenues en cultivant des cellules T dans des formulations qui comprennent des combinaisons de cellules dendritiques et de cellules soit tumorales, soit infectées par un virus. Ces formulations comprennent de manière générale un hybridome d'au moins une cellule dendritique fusionnée à au moins une cellule qui est soit tumorale, soit infectée par un virus, ou des co-cultures de cellules dendritiques et de cellules soit tumorales, soit infectées par un virus. Les cellules T ainsi obtenues peuvent être utilisées dans des procédés d'immunothérapie par le transfert adoptif chez le patient de cellules T spécifiques à un antigène et autologues, ceci à l'aide de techniques bien établies. Ces cellules peuvent être utilisées comme agents permettant d'identifier des antigènes de tumeurs, et d'établir des modèles animaux.
CA002367590A 1999-03-31 2000-03-30 Induction in vitro de cellules t specifiques a un antigene a l'aide d'immunogenes derives de cellules dendritiques-cellules tumorales ou de cellules dendritiques-cellules virales Abandoned CA2367590A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28267999A 1999-03-31 1999-03-31
US09/282,679 1999-03-31
PCT/US2000/008472 WO2000057705A1 (fr) 1999-03-31 2000-03-30 Induction in vitro de cellules t specifiques a un antigene a l'aide d'immunogenes derives de cellules dendritiques-cellules tumorales ou de cellules dendritiques-cellules virales

Publications (1)

Publication Number Publication Date
CA2367590A1 true CA2367590A1 (fr) 2000-10-05

Family

ID=23082644

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002367590A Abandoned CA2367590A1 (fr) 1999-03-31 2000-03-30 Induction in vitro de cellules t specifiques a un antigene a l'aide d'immunogenes derives de cellules dendritiques-cellules tumorales ou de cellules dendritiques-cellules virales

Country Status (6)

Country Link
EP (1) EP1168924A4 (fr)
JP (1) JP2002539805A (fr)
CN (1) CN1353575A (fr)
AU (1) AU4183100A (fr)
CA (1) CA2367590A1 (fr)
WO (1) WO2000057705A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050169898A1 (en) 1997-04-15 2005-08-04 Jianlin Gong Cell fusions and methods of making and using the same
ATE388237T1 (de) 1997-04-15 2008-03-15 Dana Farber Cancer Inst Inc Dendritische zellhybride
EP1226235A2 (fr) * 1999-10-22 2002-07-31 LESKOVAR, Peter Constructions cellulaires adaptees a l'immunotherapie, leur production et leur utilisation
DE60130634T2 (de) * 2000-02-11 2008-07-17 Dana-Farber Cancer Institute, Inc., Boston Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
DE10164819A1 (de) 2001-11-20 2005-05-19 Deml, Ludwig, Dr. Verfahren zur Identifizierung von Zielepitopen der T-Zell-vermittelten Immunantwort und zum Nachweis Epitop-spezifischer T-Zellen
SI2511301T1 (en) 2006-08-04 2018-05-31 MedImmune Limited, Human antibodies to ERBB 2
DE102010037622B4 (de) 2010-09-17 2012-07-12 Lophius Biosciences Gmbh Verfahren zum Nachweis, Differenzieren und Quantifizieren von T-Zellpopulationen mittels der Reverse Transkription quantitativen Real-Time PCR (RT-qPCR) Technologie
EP2606897A1 (fr) 2011-12-22 2013-06-26 Laboratorios Del. Dr. Esteve, S.A. Procédés et compositions pour le traitement des maladies causées par les virus enveloppés
CN102827826B (zh) * 2012-09-11 2017-07-04 赵永祥 一种诱导树突状细胞与肿瘤细胞融合的方法
WO2016145578A1 (fr) 2015-03-13 2016-09-22 Syz Cell Therapy Co. Procédés de traitement du cancer au moyen de lymphocytes t activés
CN104830793A (zh) * 2015-05-05 2015-08-12 杨光华 基于lmp-1抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途
JP7271175B2 (ja) * 2015-05-08 2023-05-11 ウィルソン ウォルフ マニュファクチャリング 試験のための改良された培養方法と装置
EP3316897A4 (fr) * 2015-07-02 2019-03-13 Primevax Immuno-Oncology, Inc. Compositions et procédés pour polythérapie utilisant le virus de la dengue et des cellules dendritiques
EP3353287B1 (fr) 2015-09-26 2022-03-09 Primevax Immuno-Oncology, Inc. Compositions et procédés pour produire des cellules dendritiques
CN105532575A (zh) * 2016-01-14 2016-05-04 中国科学院昆明动物研究所 一种单纯疱疹病毒感染树鼩动物模型的构建、评估方法及其应用
CA3082779A1 (fr) 2016-11-16 2018-05-24 PrimeVax Immuno-Oncology, Inc. Immunotherapies d'association pour le traitement du cancer
CA3049225A1 (fr) 2017-01-04 2018-07-12 PrimeVax Immuno-Oncology, Inc. Compositions et methodes de therapie avec le virus de la dengue
WO2019183924A1 (fr) 2018-03-30 2019-10-03 Syz Cell Therapy Co. Procédés améliorés de thérapie cellulaire spécifique à l'antigène

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0839044B1 (fr) * 1995-03-31 2005-05-18 Universite Libre De Bruxelles Cellules dendritiformes/cellules tumorales hybrides deservant a provoquer une reponse antitumorale
ATE388237T1 (de) * 1997-04-15 2008-03-15 Dana Farber Cancer Inst Inc Dendritische zellhybride
JP2002500872A (ja) * 1998-01-26 2002-01-15 ジェンザイム・コーポレーション 免疫エフェクター細胞ハイブリッド

Also Published As

Publication number Publication date
EP1168924A4 (fr) 2002-09-04
WO2000057705A1 (fr) 2000-10-05
CN1353575A (zh) 2002-06-12
AU4183100A (en) 2000-10-16
EP1168924A1 (fr) 2002-01-09
JP2002539805A (ja) 2002-11-26

Similar Documents

Publication Publication Date Title
Wang et al. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines
US7670611B2 (en) Cancer immunotherapy with semi-allogeneic cells
CA2367590A1 (fr) Induction in vitro de cellules t specifiques a un antigene a l'aide d'immunogenes derives de cellules dendritiques-cellules tumorales ou de cellules dendritiques-cellules virales
AU2003302504B2 (en) Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors
US20110268767A1 (en) Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses
US20100303868A1 (en) Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
Dhodapkar et al. Active immunization of humans with dendritic cells
AU2016243629A1 (en) Compositions and methods of treating cancer
Tsang et al. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells
Cho et al. In vitro induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses
Schreurs et al. Dendritic cell-based vaccines: from mouse models to clinical cancer immunotherapy
US20050042751A1 (en) Generation and use of new types of dendritic cells
US20190125848A1 (en) Dendritic cell-extracellular vesicle fusions and methods of using same
AU2016243626A1 (en) Compositions and methods of treating multiple myeloma
Engleman Dendritic cells: potential role in cancer therapy
US20050170503A1 (en) In vitro induction of antigen-specific T-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens
Peshwa et al. Generation of primary peptide-specific CD8+ cytotoxic T-lymphocytes in vitro using allogeneic dendritic cells
Rodeberg et al. In vitro induction of immune responses to shared tumor-associated antigens in rhabdomyosarcoma
Asada et al. Combination vaccine of dendritic cells (DCs) and T cells effectively suppressed preestablished malignant melanoma in mice
US20060153821A1 (en) Induction of tumor and viral immunity using antigen presenting cell co-culture products and fusion products
AU2017356295A1 (en) Compositions and methods of treating cancer
Ponsaerts Dendritic cell vaccines for immunity and tolerance: mRNA electroporation as a tool for efficient gene transfer
AU2007202210A1 (en) Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors

Legal Events

Date Code Title Description
FZDE Discontinued
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载